Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of fixed-dose laroprovstat + rosuvastatin in lipid-lowering-treatment-naive adults with elevated LDL-C
MOH_2026-08-18_016996Phase 3Not yet recruiting
- Sponsor
- AstraZeneca
- Start
- Jul 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of laroprovstat and rosuvastatin in hypercholesterolemia and dyslipidemia (4 arms), sponsored by AstraZeneca. Primary endpoint: Change in LDL-C. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
laroprovstatrosuvastatin
03
Conditions
hypercholesterolemiadyslipidemia
Beyond the preview
Go deeper on MOH_2026-08-18_016996.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2026-08-18_016996.